Overview of Rufinamide
Rufinamide, with the NDC code 31722-0598, is a medication manufactured by Camber Pharmaceuticals, Inc. It is primarily used in the treatment of seizures associated with Lennox-Gastaut syndrome, a severe form of epilepsy[1][4].
Current Market Status
As of the latest data, Rufinamide (NDC: 31722-0598) is still an active product in Camber Pharmaceuticals' portfolio, indicating no recent deletions or discontinuations[1][4].
Price Trends in the Pharmaceutical Market
The pharmaceutical market is experiencing significant price inflation, which can impact the pricing of drugs like Rufinamide. Here are some key trends:
General Drug Price Inflation
Vizient, Inc. projects a 3.8% to 3.81% increase in drug prices for 2025, driven largely by specialty pharmaceuticals, including those for chronic and complex conditions[2][3].
Specialty Pharmaceuticals
Specialty pharmaceuticals, which include medications for conditions like epilepsy, are expected to see a higher price increase of around 4.18%. This is due to the increasing utilization of these medications and the introduction of new, often high-cost treatments[3].
Generic Drug Price Increases
While generic drugs generally have lower price increases compared to brand-name drugs, there have been instances of significant price hikes. For example, the Oregon Drug Price Transparency Program reported a median price increase of 19.9% for generic drugs in 2022, with some generic drugs experiencing much higher increases[5].
Factors Influencing Rufinamide Pricing
Several factors can influence the pricing of Rufinamide:
Supply and Demand
The demand for epilepsy treatments remains steady, and any disruptions in supply can lead to price fluctuations.
Regulatory Environment
Regulatory changes, such as those related to drug price transparency and affordability boards, can impact pricing strategies. For instance, Oregon's Drug Price Transparency Program requires manufacturers to report price increases and new high-cost drugs, which can lead to greater scrutiny and potential price controls[5].
Market Competition
The presence of other epilepsy medications and the introduction of new treatments can influence pricing. However, Rufinamide's specific use in treating Lennox-Gastaut syndrome gives it a niche market position.
Price Projections
Given the current trends:
Short-Term Projections
For 2025, it is likely that Rufinamide will experience a price increase in line with the overall pharmaceutical market inflation rate of around 3.8% to 3.81%[2][3].
Long-Term Projections
In the long term, the price of Rufinamide could be influenced by the growing use of specialty pharmaceuticals and any changes in the regulatory environment. If there is increased competition from new epilepsy treatments or biosimilars, this could potentially stabilize or reduce prices.
Key Takeaways
- Market Position: Rufinamide remains an active and necessary medication for treating Lennox-Gastaut syndrome.
- Price Trends: Expected to follow general pharmaceutical market inflation rates.
- Regulatory Impact: Subject to regulatory scrutiny and potential price controls.
- Market Competition: Niche market position but subject to competition from new treatments.
FAQs
What is Rufinamide used for?
Rufinamide is used primarily in the treatment of seizures associated with Lennox-Gastaut syndrome, a severe form of epilepsy.
Who manufactures Rufinamide with NDC 31722-0598?
Camber Pharmaceuticals, Inc. manufactures Rufinamide with the NDC code 31722-0598.
What is the projected price increase for pharmaceuticals in 2025?
The projected price increase for pharmaceuticals in 2025 is around 3.8% to 3.81%, driven largely by specialty pharmaceuticals.
How does regulatory environment impact drug pricing?
Regulatory changes, such as drug price transparency programs and potential upper payment limits, can lead to greater scrutiny and potential price controls.
What are the factors influencing the price of Rufinamide?
Factors include supply and demand, regulatory environment, and market competition from other epilepsy treatments.
Sources
- Find a Code: Camber Pharmaceuticals, Inc. - List of Drugs - NDC Labeler.
- Vizient Inc.: Vizient projects drug price inflation at 3.81%.
- Vizient Inc.: Vizient Projects 3.8% Drug Price Increase Driven by Specialty Pharmaceuticals.
- Find a Code: Camber Pharmaceuticals - List of Drugs - NDC Labeler/Manufacturer.
- Oregon Department of Consumer and Business Services: Prescription Drug Price Transparency Results and Recommendations.
